What is Cindy Eckert's mission with Sprout Pharmaceuticals?

Cindy Eckert, the CEO of Sprout Pharmaceuticals, is on a mission to destigmatize women's sexual health and empower them through her company's signature product, the women's libido drug Addyi.

How has Addyi's popularity changed in recent years?

In the last few years, Addyi's popularity has surged as cultural attitudes around women's sexual health have shifted, with growing openness around menopause, perimenopause, and women's sexual wellness. Regulatory changes have also made Addyi more accessible to patients.

What challenges did Cindy Eckert face in getting Addyi approved?

Cindy Eckert faced a decade-long battle to get the FDA to approve Addyi, Sprout's women's libido drug. She had to overcome initial skepticism and backlash, with critics accusing her of trying to "medicalize" natural fluctuations in women's sexual desire.

Home / Health / Determined CEO Reclaims Her "Pink Pill" Empire for Women's Health

Determined CEO Reclaims Her "Pink Pill" Empire for Women's Health

16 Nov

•

Summary

Cindy Eckert's lifelong commitment to her "pink" brand
Her decade-long battle to get FDA approval for women's libido drug Addyi
Sprout Pharmaceuticals' recent resurgence and growing popularity of Addyi

Determined CEO Reclaims Her "Pink Pill" Empire for Women's Health

In November 2025, Cindy Eckert, the co-founder and CEO of Sprout Pharmaceuticals, is celebrating the resurgence of her company's signature product, the women's libido drug Addyi. After a decade-long battle to get the "little pink pill" approved by the FDA and then regain control of her company, Eckert's persistence has paid off as Addyi's popularity has soared in recent years.

Eckert's unwavering commitment to her "pink" brand and mission to destigmatize women's sexual health has been central to Addyi's journey. From the pink-themed decor of her home to the company's "unapologetically pink" office, Eckert has embraced the color as a symbol of her cause. This dedication has helped her weather the initial backlash and skepticism surrounding Addyi, as critics accused Sprout of trying to "medicalize" natural fluctuations in women's sexual desire.